Rapid-deployment aortic valve replacement in high-risk patients with severe endocarditis.


Journal

The Journal of cardiovascular surgery
ISSN: 1827-191X
Titre abrégé: J Cardiovasc Surg (Torino)
Pays: Italy
ID NLM: 0066127

Informations de publication

Date de publication:
Dec 2020
Historique:
pubmed: 20 6 2020
medline: 20 1 2021
entrez: 20 6 2020
Statut: ppublish

Résumé

Surgical management of aortic valve endocarditis in high risk patients is controversial and the ideal treatment has not been found yet. We describe a selected series of eight patients treated with rapid-deployment aortic valve prosthesis as a therapeutic solution for minimizing the risks associated with annulus manipulation in case of severe aortic infective endocarditis. Eight consecutive patients (five men and three women) with a mean age of 74.3±7.2 years, mean logistic EuroSCORE II of 16.0%±0.1%, affected by aortic native (1 patient), or prosthetic valve endocarditis (7 patients), were treated with Edwards Intuity Elite implantation. Hemodynamic performance and infective data were collected pre-, intra-, and postoperatively with a mean follow-up of 2.7±0.7 years. One case of in-hospital mortality was noted. None of the patients had any embolic or infective complication postoperatively. The cardiopulmonary bypass and aortic cross-clamp times were 148.4±41.6 and 90.5±25.3 min, respectively. The postoperative echocardiographic controls indicated a mean transvalvular gradient of 16.7±3.0 mmHg and one case of paravalvular leaks (2 +). Two patients underwent epigastric permanent pacemaker implantation. During the follow-up, seven patients were alive, with no evidence of symptoms or recurrences of endocarditis or embolic episodes. No new paravalvular leaks were noted, and the mean gradient on the valves was 12.4±3.4 mmHg. Rapid deployment aortic valve replacement in selected very high-risk patients affected by infective endocarditis could be a reasonable choice with acceptable results. However, further studies are needed to confirm these results.

Sections du résumé

BACKGROUND BACKGROUND
Surgical management of aortic valve endocarditis in high risk patients is controversial and the ideal treatment has not been found yet. We describe a selected series of eight patients treated with rapid-deployment aortic valve prosthesis as a therapeutic solution for minimizing the risks associated with annulus manipulation in case of severe aortic infective endocarditis.
METHODS METHODS
Eight consecutive patients (five men and three women) with a mean age of 74.3±7.2 years, mean logistic EuroSCORE II of 16.0%±0.1%, affected by aortic native (1 patient), or prosthetic valve endocarditis (7 patients), were treated with Edwards Intuity Elite implantation. Hemodynamic performance and infective data were collected pre-, intra-, and postoperatively with a mean follow-up of 2.7±0.7 years.
RESULTS RESULTS
One case of in-hospital mortality was noted. None of the patients had any embolic or infective complication postoperatively. The cardiopulmonary bypass and aortic cross-clamp times were 148.4±41.6 and 90.5±25.3 min, respectively. The postoperative echocardiographic controls indicated a mean transvalvular gradient of 16.7±3.0 mmHg and one case of paravalvular leaks (2 +). Two patients underwent epigastric permanent pacemaker implantation. During the follow-up, seven patients were alive, with no evidence of symptoms or recurrences of endocarditis or embolic episodes. No new paravalvular leaks were noted, and the mean gradient on the valves was 12.4±3.4 mmHg.
CONCLUSIONS CONCLUSIONS
Rapid deployment aortic valve replacement in selected very high-risk patients affected by infective endocarditis could be a reasonable choice with acceptable results. However, further studies are needed to confirm these results.

Identifiants

pubmed: 32558526
pii: S0021-9509.20.11349-1
doi: 10.23736/S0021-9509.20.11349-1
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

769-775

Auteurs

Antonio Piperata (A)

Department of Valvulopathies, Cardiac Surgery and Adult Interventional Cardiology, de Haut-Lévèque Hospital, University Hospital of Bordeaux, Bordeaux, France - a.piperata88@gmail.com.
Department of Cardio-Vascular, Thoracic Surgery and Lung Transplantation, UCL Namur University Hospital, Catholic University of Louvain, Yvoir, Belgium - a.piperata88@gmail.com.

Gregory Kalscheuer (G)

Department of Valvulopathies, Cardiac Surgery and Adult Interventional Cardiology, de Haut-Lévèque Hospital, University Hospital of Bordeaux, Bordeaux, France.
Department of Cardiology, Thoracic and Vascular Sciences, University of Padua, Padua, Italy.

Alexandre Metras (A)

Department of Valvulopathies, Cardiac Surgery and Adult Interventional Cardiology, de Haut-Lévèque Hospital, University Hospital of Bordeaux, Bordeaux, France.

Mathieu Pernot (M)

Department of Valvulopathies, Cardiac Surgery and Adult Interventional Cardiology, de Haut-Lévèque Hospital, University Hospital of Bordeaux, Bordeaux, France.

Waleed Albadi (W)

Department of Valvulopathies, Cardiac Surgery and Adult Interventional Cardiology, de Haut-Lévèque Hospital, University Hospital of Bordeaux, Bordeaux, France.

Saud Taymoor (S)

Department of Valvulopathies, Cardiac Surgery and Adult Interventional Cardiology, de Haut-Lévèque Hospital, University Hospital of Bordeaux, Bordeaux, France.

Julien Peltan (J)

Department of Valvulopathies, Cardiac Surgery and Adult Interventional Cardiology, de Haut-Lévèque Hospital, University Hospital of Bordeaux, Bordeaux, France.

Pierre Oses (P)

Department of Valvulopathies, Cardiac Surgery and Adult Interventional Cardiology, de Haut-Lévèque Hospital, University Hospital of Bordeaux, Bordeaux, France.

Laurent Barandon (L)

Department of Valvulopathies, Cardiac Surgery and Adult Interventional Cardiology, de Haut-Lévèque Hospital, University Hospital of Bordeaux, Bordeaux, France.

Tomaso Bottio (T)

Department of Cardiology, Thoracic and Vascular Sciences, University of Padua, Padua, Italy.

Gino Gerosa (G)

Department of Cardiology, Thoracic and Vascular Sciences, University of Padua, Padua, Italy.

Louis Labrousse (L)

Department of Valvulopathies, Cardiac Surgery and Adult Interventional Cardiology, de Haut-Lévèque Hospital, University Hospital of Bordeaux, Bordeaux, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH